US Stock Market Moves: CG Oncology Plunges on October 6 Due to Underperforming Results, High Valuation Correction, and Dilution from Additional Issuance

CG Oncology October 6 Decline Analysis

Keywords: underperforming results, high valuation correction, additional issuance dilution

1. On August 6, 2026, the company's adjusted loss per share was $0.90, higher than the expected $0.70; quarterly revenue was $1.16 million, lower than expected, with net loss widening year-on-year.

2. On September 3, 2026, the company's price-to-book ratio was about 6.4 times, higher than the biotech industry average of approximately 2.5 times; cumulative increase in 2026 reached 53.56%, putting significant pressure on valuation correction.

3. On August 6, 2026, the company increased the quota for ordinary shares issuance under the at-the-market sales agreement by $500 million, and subsequent financing may bring equity dilution pressure.

(Disclaimer: This content is summarized and generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)